|
1
|
Peiretti M, Zapardiel I, Zanagnolo V,
Landoni F, Morrow CP and Maggioni A: Management of recurrent
cervical cancer: A review of the literature. Surg Oncol.
21:e59–e66. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cerrotta A, Gardan G, Cavina R,
Raspagliesi F, Stefanon B, Garassino I, Musumeci R, Tana S and De
Palo G: Concurrent radiotherapy and weekly paclitaxel for locally
advanced or recurrent squamous cell carcinoma of the uterine
cervix. A pilot study with intensification of dose. Eur J Gynaecol
Oncol. 23:115–119. 2002.PubMed/NCBI
|
|
3
|
Elble RC, Walia V, Cheng HC, Connon CJ,
Mundhenk L, Gruber AD and Pauli BU: The putative chloride channel
hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem.
281:29448–29454. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Walia V, Ding M, Kumar S, Nie D, Premkumar
LS and Elble RC: hCLCA2 is a p53-inducible inhibitor of breast
cancer cell proliferation. Cancer Res. 69:6624–6632.
2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Connon CJ, Kawasaki S, Yamasaki K,
Quantock AJ and Kinoshita S: The quantification of hCLCA2 and
colocalisation with integrin beta4 in stratified human epithelia.
Acta Histochem. 106:421–425. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ramena G, Yin Y, Yu Y, Walia V and Elble
RC: CLCA2 interactor EVA1 is required for mammary epithelial cell
differentiation. PLoS One. 11(e0147489)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bart G, Hämäläinen L, Rauhala L, Salonen
P, Kokkonen M, Dunlop TW, Pehkonen P, Kumlin T, Tammi MI,
Pasonen-Seppänen S and Tammi RH: rClca2 is associated with
epidermal differentiation and is strongly downregulated by
ultraviolet radiation. Br J Dermatol. 171:376–387. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Grigsby PW, Massad LS, Mutch DG, Powell
MA, Thaker PH, McCourt C, Hagemann A, Fuh K, Kuroki L, Schwarz JK,
et al: FIGO 2018 staging criteria for cervical cancer: Impact on
stage migration and survival. Gynecol Oncol. 157:639–643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang J, Ou J, Guo Y, Dai T, Li X, Liu J,
Xia M, Liu L and He M: TBLR1 is a novel prognostic marker and
promotes epithelial-mesenchymal transition in cervical cancer. Br J
Cancer. 111:112–124. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang B, Zhang L and Zhao L, Zhou R, Ding
Y, Li G and Zhao L: LASP2 suppresses colorectal cancer progression
through JNK/p38 MAPK pathway meditated epithelial-mesenchymal
transition. Cell Commun Signal. 15(21)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Park S, Kim J, Eom K, Oh S, Kim S, Kim G,
Ahn S, Park KH, Chung D and Lee H: microRNA-944 overexpression is a
biomarker for poor prognosis of advanced cervical cancer. BMC
Cancer. 19(419)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pauli BU, Abdel-Ghany M, Cheng HC, Gruber
AD, Archibald HA and Elble RC: Molecular characteristics and
functional diversity of CLCA family members. Clin Exp Pharmacol
Physiol. 27:901–905. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pawlowski K, Lepisto M, Meinander N,
Sivars U, Varga M and Wieslander E: Novel conserved hydrolase
domain in the CLCA family of alleged calcium-activated chloride
channels. Proteins. 63:424–439. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fuller CM, Ji HL, Tousson A, Elble RC,
Pauli BU and Benos DJ: Ca(2+)-activated Cl(-) channels: A newly
emerging anion transport family. Pflugers Archiv. 443 (Suppl
1):S107–S110. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li X, Cowell JK and Sossey-Alaoui K: CLCA2
tumour suppressor gene in 1p31 is epigenetically regulated in
breast cancer. Oncogene. 23:1474–1480. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao G, Chen J, Deng Y, Gao F, Zhu J, Feng
Z, Lv X and Zhao Z: Identification of NDRG1-regulated genes
associated with invasive potential in cervical and ovarian cancer
cells. Biochem Biophys Res Commun. 408:154–159. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sasaki Y, Koyama R, Maruyama R, Hirano T,
Tamura M, Sugisaka J, Suzuki H, Idogawa M, Shinomura Y and Tokino
T: CLCA2, a target of the p53 family, negatively regulates cancer
cell migration and invasion. Cancer Biol Ther. 13:1512–1521.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Qiang YY, Li CZ, Sun R, Zheng LS, Peng LX,
Yang JP, Meng DF, Lang YH, Mei Y, Xie P, et al: Along with its
favorable prognostic role, CLCA2 inhibits growth and metastasis of
nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling.
J Exp Clin Cancer Res. 37(34)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jiang MM, Gao L, Jing Y, Ding Y, Xu YY,
Zhou MH, Ma C, Wang N, Wang W, Han XP, et al: Rapid detection of
AML1 associated fusion genes in patients with adult acute myeloid
leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue
Za Zhi. 21:821–829. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Man Y, Cao J, Jin S, Xu G, Pan B, Shang L,
Che D, Yu Q and Yu Y: Newly identified biomarkers for detecting
circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med.
234:29–40. 2014.PubMed/NCBI View Article : Google Scholar
|
